Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 What is the optimal age for starting lipid lowering treatment? A mathematical model.

Literature DB >> 10775228

What is the optimal age for starting lipid lowering treatment? A mathematical model.

S Ulrich¹, A D Hingorani, J Martin, P Vallance.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2000 PMID： 10775228 PMCID： PMC1127257 DOI： 10.1136/bmj.320.7242.1134

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

22 in total

1. Lifetime risk of developing coronary heart disease.

Authors: S Ulrich; A D Hingorani; J Martin; P Vallance
Journal: Lancet Date: 1999-03-13 Impact factor: 79.321

2. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men.

Authors: I U Haq; L E Ramsay; W W Yeo; P R Jackson; E J Wallis
Journal: Heart Date: 1999-01 Impact factor: 5.994

3. An updated coronary risk profile. A statement for health professionals.

Authors: K M Anderson; P W Wilson; P M Odell; W B Kannel
Journal: Circulation Date: 1991-01 Impact factor: 29.690

4. Lipoproteins in atherogenesis.

Authors: G Schonfeld
Journal: Artery Date: 1979-04

5. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study.

Authors: P E Leaverton; P D Sorlie; J C Kleinman; A L Dannenberg; L Ingster-Moore; W B Kannel; J C Cornoni-Huntley
Journal: J Chronic Dis Date: 1987

6. Multivariate prediction of coronary heart disease in the Western Collaborative Group Study compared to the findings of the Framingham study.

Authors: R J Brand; R H Rosenman; R I Sholtz; M Friedman
Journal: Circulation Date: 1976-02 Impact factor: 29.690

7. Management of raised blood pressure in New Zealand: a discussion document.

Authors: R Jackson; P Barham; J Bills; T Birch; L McLennan; S MacMahon; T Maling
Journal: BMJ Date: 1993-07-10

8. Cardiovascular disease risk profiles.

Authors: K M Anderson; P M Odell; P W Wilson; W B Kannel
Journal: Am Heart J Date: 1991-01 Impact factor: 4.749

9. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.

Authors: A Keech; R Collins; S MacMahon; J Armitage; A Lawson; K Wallendszus; M Fatemian; E Kearney; V Lyon; J Mindell
Journal: Eur Heart J Date: 1994-02 Impact factor: 29.983

Review 10. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Authors: R Collins; R Peto; S MacMahon; P Hebert; N H Fiebach; K A Eberlein; J Godwin; N Qizilbash; J O Taylor; C H Hennekens
Journal: Lancet Date: 1990-04-07 Impact factor: 79.321

14 in total

What is the optimal age for starting lipid lowering treatment? A mathematical model.

1. Lifetime risk of developing coronary heart disease.

2. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men.

3. An updated coronary risk profile. A statement for health professionals.

4. Lipoproteins in atherogenesis.

5. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study.

6. Multivariate prediction of coronary heart disease in the Western Collaborative Group Study compared to the findings of the Framingham study.

7. Management of raised blood pressure in New Zealand: a discussion document.

8. Cardiovascular disease risk profiles.

9. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.

Review 10. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Review 1. Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility.

2. Statins: underused by those who would benefit.

3. Optimal age for starting lipid lowering treatment. A 10 year risk of 30% should be used.

Review 4. New and emerging data from clinical trials of statins.

5. Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom.

Review 6. Should pediatric patients with hyperlipidemia receive drug therapy?

7. Treatment of dyslipidemia in the elderly.

8. Prevalence of cardiovascular risk factors in a middle-income country and estimated cost of a treatment strategy.

9. Treatment of high blood pressure and gain in event-free life expectancy.

10. The current status of primary prevention in coronary heart disease.